Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: f6792e14800b554fe673e88276e13a2e88806ba5
First added on: Feb 10, 2025